Alnylam's R&D update includes 3 halts, Alzheimer's timeline and another NASH
Alnylam Pharmaceuticals touted its high probability of success in bringing assets from Phase I to Phase III — about 62% compared to an industry average of 5% to 10% — in an R&D update Thursday.
But, even the RNAi drug developer with five medicines now under its wings will come out with the scissors and scrap studies it finds lacking, as the Boston-area biotech outlined in an investor presentation. That includes cemdisiran for kidney disease IgA nephropathy, an early-stage drug for gout and lumasiran for recurrent renal stones.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters